1933 - Fellow of the American Association for the Advancement of Science (AAAS)
His scientific interests lie mostly in Surgery, Ovarian cancer, Internal medicine, Chemotherapy and Oncology. His Surgery research includes themes of Carcinoma and Urology. His Ovarian cancer study combines topics from a wide range of disciplines, such as Stage, Gynecologic oncology, Gynecology and Disease.
His work on Cancer, Breast cancer and Proportional hazards model is typically connected to Population as part of general Internal medicine study, connecting several disciplines of science. His Chemotherapy study integrates concerns from other disciplines, such as Clinical trial and Ovary. William J. Hoskins has included themes like Radical Hysterectomy and Cervix in his Oncology study.
William J. Hoskins mostly deals with Surgery, Internal medicine, Ovarian cancer, Oncology and Chemotherapy. His biological study spans a wide range of topics, including Carcinoma and Urology. In general Internal medicine, his work in Cancer, Ovary and Ovarian carcinoma is often linked to In patient linking many areas of study.
His Ovarian cancer study combines topics in areas such as Gynecologic oncology, Disease, Pathology, Gynecology and General surgery. William J. Hoskins has researched Oncology in several fields, including Cyclophosphamide, Paclitaxel and Epithelial ovarian cancer. His work deals with themes such as Regimen and Clinical trial, which intersect with Chemotherapy.
William J. Hoskins focuses on Internal medicine, Ovarian cancer, Oncology, Surgery and Gynecology. His Ovarian cancer research is multidisciplinary, incorporating perspectives in Retrospective cohort study, Paclitaxel, Chemotherapy and Proportional hazards model. Within one scientific family, he focuses on topics pertaining to Progression-free survival under Oncology, and may sometimes address concerns connected to Cyclophosphamide.
His Surgery research incorporates elements of Disease and General surgery. The Gynecology study combines topics in areas such as Gynecologic oncology, Clinical trial, Endometrial cancer and Family medicine. His Stage research is multidisciplinary, incorporating elements of Gastroenterology, Combination chemotherapy and Cisplatin.
His primary areas of study are Surgery, Ovarian carcinoma, Ovarian cancer, Gynecology and Internal medicine. His study in the fields of Proportional hazards model, Robotic surgery and Laparotomy under the domain of Surgery overlaps with other disciplines such as Indirect costs. The study incorporates disciplines such as Neoadjuvant therapy and Chemotherapy in addition to Ovarian cancer.
His study in Chemotherapy is interdisciplinary in nature, drawing from both Randomized controlled trial and Clinical trial. His studies deal with areas such as Stage, Gastroenterology and Endometrial cancer as well as Gynecology. William J. Hoskins works mostly in the field of Internal medicine, limiting it down to topics relating to Oncology and, in certain cases, Carcinoma.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
William P. McGuire;William J. Hoskins;Mark F. Brady;Paul R. Kucera.
The New England Journal of Medicine (1996)
Impact of hospital volume on operative mortality for major cancer surgery.
Colin B. Begg;Laura D. Cramer;William J. Hoskins;Murray F. Brennan.
Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer
David S. Alberts;P. Y. Liu;Edward V. Hannigan;Robert O'Toole.
The New England Journal of Medicine (1996)
Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.
M Markman;R Rothman;T Hakes;B Reichman.
Journal of Clinical Oncology (1991)
The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma.
William J. Hoskins;William P. McGuire;Mark F. Brady;Howard D. Homesley.
American Journal of Obstetrics and Gynecology (1994)
Symptom prevalence, characteristics and distress in a cancer population
R. K. Portenoy;H. T. Thaler;A. B. Kornblith;J. McCarthy Lepore.
Quality of Life Research (1994)
Ovarian Cancer: Screening, Treatment, and Follow-up
Vicki Seltzer;Bruce H. Drukker;Brenda W. Gillespie;Lynn M. Gossfeld.
The influence of cytoreductive surgery on recurrence-free interval and survival in small volume stage III epithelial ovarian cancer : a Gynecologic Oncology Group study
W J Hoskins;B N Bundy;J T Thigpen;G A Omura.
Gynecologic Oncology (1992)
Clinicopathologic Features of BRCA-Linked and Sporadic Ovarian Cancer
Jeff Boyd;Yukio Sonoda;Mark G. Federici;Faina Bogomolniy.
Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125.
G. J. S. Rustin;A. E. Nelstrop;P. Mcclean;M. F. Brady.
Journal of Clinical Oncology (1996)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: